Strategic capital HCRx is a royalty and debt capital provider with a history of multi-structure financing, offering flexible capital solutions that could be pitched to biopharma assets seeking monetization, revenue participation, or bespoke debt instruments.

Portfolio depth The firm has invested in over 110 biopharma products and manages more than 7 billion in commitments, indicating a broad exposure base and potential cross-sell opportunities across similar asset classes and stages.

Deep partnerships Recent and notable collaborations, including a major BridgeBio royalty monetization and ongoing capital relationships, signal opportunities to co-structure new deals with existing counterparties or leverage existing relationships for referrals.

Global reach With offices in multiple strategic hubs (NY, Stamford, SF, Boston, London, Miami) and a diverse senior team, HCRx has geographic coverage that can facilitate cross-border financings and localized deal structuring for regional assets.

Growth momentum KKR’s majority ownership and ongoing financings (senior secured facilities, royalties, revenue participation) suggest a sustained growth trajectory and potential for opportunistic financings across late-stage to near-commercial assets.